ACOBIOM

25 years of expertise in RNA/DNA biomarkers. Development of in-vitro diagnostics to personalize therapies in oncology. A 1st blood-based PCR test on the market.

  • Stage Full Product Ready
  • Industry Medical Devices and Equipment
  • Location Montpellier, France
  • Currency EUR
  • Founded June 1999
  • Employees 8
  • Incorporation Type C-corp
  • Website acobiom.com

Company Summary

Acobiom is specialized in the identification and evaluation of RNA/DNA biomarkers, as well as in the development of in-vitro diagnostics for precision medicine, from R&D to commercialization.
For instance, the company developed Gemcitest®, a CE-marked blood-based PCR-test that predicts the patient response to a gemcitabine-based first-line chemotherapy for pancreatic cancer. Gemcitest is distributed in Europe by Eurobio Scientific (Euronext).

Team

  • Didier RITTER
    CEO

    Didier Ritter has over 25 years' experience in the life cycle of an innovative life sciences company: business development, strategic alliances, project management, fundraising and financing. Chairman & founder of Acobiom. Chairman of Biomed Alliance Méditerranée, cluster of life sciences companies (Occitanie). Board member of Kyomed Innov (e-health, medical devices).
    Diplomas: Master in biology (Montpellier University), MBA (Montpellier IAE).

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free